Benlysta (belimumab) - GSK
Lupkynis (voclosporin) - Aurinia Pharma
Investigating Canadians' information needs related to lupus: A Google Trends analysis of online search query data (ACR Convergence 2025) - Sep 15, 2025 - Abstract #0188; Pres time: Oct 26, 2025; 10:30 AM - 12:30 PM; Location: Hall F1; In Person; "Additional peaks were observed across Canada in July 2009 (RV=0.58), September 2016 (RV=0.69), and September 2017 (RV=0.78), all of which were correlated with milestones in the development and eventual approval of belimumab for SLE. Similarly, a peak in August 2016 (RV=0.66) was associated with positive Phase II trials for voclosporin... An understanding of the information needs of the general public related to SLE, and how they vary spatially, is critical for designing and implementing targeted and effective patient education interventions. To this end, these research results will be shared and triangulated with the knowledge needs of advocacy organizations and the realities of lived SLE experience, through a deliberative dialogue with key stakeholders from across Canada. This research and deliberative dialogue will set a foundation for the design and implementation of relevant interventions to effectively reduce SLE-related health disparities and improve..." 
Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Novel Coronavirus Disease
https://eppro02.ativ.me/web/page.php?page=IntHtml&project=ACR25&id=3185490
 
Taylor Williamson1; Emily Shantz1; Susan Elliott1; Christine Sperling2; Karen H. Costenbader3; May Choi4
 
Sep 15, 2025
 
Prev Next